G6PD and Plasmodium vivax malaria: As part of a large multicentre, randomised controlled clinical trial of primaquine in G6PD normal patients with vivax malaria (IMPROV) [18], patients diagnosed with G6PDd were excluded from that main trial and enrolled into an observational study to assess the safety and efficacy of PQ8W over 12 months of follow up.